An open safety study with the monoaminergic stabilizer (-)-OSU6162 in patients with mental fatigue and related vitality and wakefulness disturbances associated with neurologiacal disorders, eg. Parkinson's disease, Huntington's disease, brain trauma, stroke, myalgic encephalomyelitis and narcolepsy

Trial Profile

An open safety study with the monoaminergic stabilizer (-)-OSU6162 in patients with mental fatigue and related vitality and wakefulness disturbances associated with neurologiacal disorders, eg. Parkinson's disease, Huntington's disease, brain trauma, stroke, myalgic encephalomyelitis and narcolepsy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jun 2016

At a glance

  • Drugs OSU 6162 (Primary)
  • Indications Chronic fatigue syndrome
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top